Mucosal and Systemic Adjuvant Effects of Cholera Toxin and Cry1Ac Protoxin on the Specific Antibody Response to HIV-1 C4/V3 Peptides Are Different and Depend on the Antigen Co-administered

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Viral immunology

• Publication date

  2005-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/VIM.2005.18.695PMID 16359236
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Automated synthesis and use of N-chloroacetyl-modified peptides for the preparation of synthetic peptide polymers and peptide-protein immunogens.

  2009cited by this paper
• A rational design of synthetic peptide vaccine with a built-in adjuvant. A modular approach for unambiguity.

  2009cited by this paper
• Mucosal HIV vaccines: where are we now?

  2004cited by this paper
• Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines.

  2004cited by this paper
• A comparative study of different presentation strategies for an HIV peptide immunogen.

  2004cited by this paper
• Clostridium difficile Toxin A Carboxyl-Terminus Peptide Lacking ADP-Ribosyltransferase Activity Acts as a Mucosal Adjuvant

  2004cited by this paper
• Intranasal Coadministration of the Cry1Ac Protoxin with Amoebal Lysates Increases Protection against Naegleria fowleri Meningoencephalitis

  2004cited by this paper
• Intranasal Cry1Ac Protoxin is an Effective Mucosal and Systemic Carrier and Adjuvant of Streptococcus pneumoniae Polysaccharides in Mice

  2003cited by this paper
• Microparticles as vaccine adjuvants and delivery systems

  2003cited by this paper
• Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges.

  2003cited by this paper
• The role of mucosal immunity in prevention of HIV transmission.

  2003cited by this paper
• Impairment by Mucosal Adjuvants and Cross-Reactivity with Variant Peptides of the Mucosal Immunity Induced by Injection of the Fusion Peptide PADRE-ELDKWA

  2003cited by this paper
• Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization

  2002cited by this paper
• A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants.

  2002cited by this paper
• Lipopeptide vaccines--yesterday, today, and tomorrow.

  2002cited by this paper
• Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.

  2002cited by this paper
• The Pulmonary Environment Promotes Th2 Cell Responses After Nasal-Pulmonary Immunization with Antigen Alone, but Th1 Responses Are Induced During Instances of Intense Immune Stimulation1

  2001cited by this paper
• Study of different coupling agents in the conjugation of a V3‐based synthetic MAP to carrier proteins

  2001cited by this paper
• Intranasal, rectal and intraperitoneal immunization with protoxin Cry1Ac from Bacillus thuringiensis induces compartmentalized serum, intestinal, vaginal and pulmonary immune responses in Balb/c mice.

  2000cited by this paper
• Immunogenicity of Neutralizing Epitopes on Multiple–Epitope Vaccines against HIV–1

  2000cited by this paper
• Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.

  1999cited by this paper
• Bacillus thuringiensis Cry1Ac Protoxin is a Potent Systemic and Mucosal Adjuvant

  1999cited by this paper
• Immunogenicity of the GPGRAFY epitope on synthetic peptides.

  1999cited by this paper
• Epitope vaccine: a new strategy against HIV-1.

  1999cited by this paper
• Mucosal immunity and tolerance: relevance to vaccine development

  1999cited by this paper
• Different antiamebic antibody isotype patterns in the large and small intestine after local and systemic immunization of mice with glutaraldehyde fixed Entamoeba histolytica trophozoites.

  1999cited by this paper
• Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models.

  1998cited by this paper
• Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice.

  1997cited by this paper
• A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin.

  1997cited by this paper
• Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.

  1997cited by this paper
• Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases.

  1997cited by this paper
• Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).

  1996cited by this paper
• Oral immunization of interleukin-4 (IL-4) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses

  1996cited by this paper
• Synthetic vaccine against foot-and-mouth disease based on a palmitoyl derivative of the VP1 protein 135-159 fragment of the A22 virus strain.

  1996cited by this paper
• Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4.

  1995cited by this paper
• Liposomes as immunoadjuvants and vaccine carriers: antigen entrapment.

  1994cited by this paper
• In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delayed-type hypersensitivity by a 23-amino acid peptide from the highly conserved region in major core protein p24.

  1994cited by this paper
• Conjugation of synthetic peptides to carrier iscoms: factors affecting the immunogenicity of the conjugate.

  1994cited by this paper
• Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems.

  1993cited by this paper
• Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.

  1993cited by this paper
• Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen.

  1993cited by this paper
• Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues

  1993cited by this paper
• Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.

  1991cited by this paper
• Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

  1991cited by this paper
• Development of artificial vaccines against HIV using defined epitopes

  1991cited by this paper
• Neutralization of HIV‐1: a paradox of humoral proportions

  1991cited by this paper
• Hyperexpression of a Bacillus thuringiensis delta-endotoxin-encoding gene in Escherichia coli: properties of the product.

  1990cited by this paper
• Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

  1990cited by this paper
• Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1

  1990cited by this paper
• Insecticidal crystal proteins of Bacillus thuringiensis.

  1989cited by this paper
• Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.

  1989cited by this paper
• Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system.

  1988cited by this paper
• Enhancement of peptide immunogenicity by linear polymerization

  1988cited by this paper
• Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

  1988cited by this paper
• A New Class of Polymers: Starburst-Dendritic Macromolecules

  1985cited by this paper

• Plasmid vector(s) in Bacillus thuringiensis harbor genes for insect pest control and for neglected infectious diseases in humans

  2024cites this paper
• Literature review in support of adjuvanticity/immunogenicity assessment of proteins

  2019cites this paper
• In silico search, chemical characterization and immunogenic evaluation of amino-terminated G4-PAMAM-HIV peptide complexes using three-dimensional models of the HIV-1 gp120 protein.

  2019cites this paper
• Cry1Ac toxin induces macrophage activation via ERK1/2, JNK and p38 mitogen-activated protein kinases.

  2016cites this paper
• An overview of the safety and biological effects of Bacillus thuringiensis Cry toxins in mammals

  2016cites this paper
• Assessment of potential adjuvanticity of Cry proteins.

  2016cites this paper
• Recombinant influenza viruses as a vaccine vector for HIV

  2015cites this paper
• Protein Allergy and GMOs

  2014cites this paper
• A chloroplast-derived C4V3 polypeptide from the human immunodeficiency virus (HIV) is orally immunogenic in mice

  2012cites this paper
• Bacteria and their toxins tamed for immunotherapy.

  2012cites this paper
• Mucosal HIV transmission and vaccination strategies through oral compared with vaginal and rectal routes

  2010cites this paper
• Development of alternative micro and nanoparticulate polymeric systems for mucosal delivery of Streptococcus equi antigens

  2008cites this paper